Antares Pharma's Total Assets for the quarter that ended in Mar. 2022 was $255.7 Mil.
Warning Sign:
If a company builds asset at 42.1% a year, faster than its revenue growth rate of 29.7% over the past 5 years, it means that the company may be getting less efficent.
During the past 12 months, Antares Pharma's average Total Assets Growth Rate was 18.80% per year.
During the past 3 years, the average Total Assets Growth Rate was 46.60% per year.
During the past 5 years, the average Total Assets Growth Rate was 42.10% per year.
During the past 10 years, the average Total Assets Growth Rate was 28.50% per year.
During the past 13 years, Antares Pharma's highest 3-Year average Total Assets Growth Rate was 69.70%. The lowest was -27.10%. And the median was 18.00%.
The historical data trend for Antares Pharma's Total Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
Antares Pharma's Total Assets for the fiscal year that ended in Dec. 2021 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Antares Pharma (NAS:ATRS) Total Assets Explanation
Note:
The Net Income data used here is four times the quarterly (Mar. 2022) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
Antares Pharma's Asset Turnover for the quarter that ended in Mar. 2022 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
Antares Pharma Total Assets Related Terms
Thank you for viewing the detailed overview of Antares Pharma's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.
Antares Pharma (Antares Pharma) Business Description
Antares Pharma Inc is a specialty pharmaceutical company. It is focused on the development and commercialization of self-administered parenteral pharmaceutical products and technologies. The company's products include OTREXUP, Elestrin, Gelnique, Makena, and others.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ATRS has been successfully added to your 